0 Bedömningar
ID

21066

Beskrivning

An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01902862

Länk

https://clinicaltrials.gov/show/NCT01902862

Nyckelord

Versioner (1)
  1. 2017-04-07 2017-04-07 -
Uppladdad den

7 april 2017

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

  • Senaste
  • Äldsta
  • Önskad
  • Senaste
    • Senaste
    • Äldsta
    • Önskad

    Inga kommentarer

    Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

    Eligibility Lymphoma, Follicular NCT01902862

    Engelsk

    Eligibility Lymphoma, Follicular NCT01902862

    1 Formulär  
    Inclusion Criteria
    Beskrivning

    Inclusion Criteria

    Alias
    UMLS CUI
    C1512693
    participants with histologically confirmed relapsed or refractory follicular stage iii or iv, grade 1 and 2, cluster of differentiation 20 plus (cd20+) lymphoma (who-world health organization) that requires therapy
    Beskrivning

    Lymphoma, Follicular; histological diagnosis; Recurrent disease; Refractory Disease | Lymphoma stage | Cell positive for CD20 antigen

    Datatyp

    boolean

    Alias
    UMLS CUI [1,1]
    C0024301
    UMLS CUI [1,2]
    C0679557
    UMLS CUI [1,3]
    C0277556
    UMLS CUI [1,4]
    C1514815
    UMLS CUI [2]
    C1272836
    UMLS CUI [3]
    C0882818
    participants in whom treatment with rituximab is planned after greater than or equal to 2 cytostatic (inhibition of cell growth) previous therapies
    Beskrivning

    rituximab planned, prior chemotherapy

    Datatyp

    boolean

    Alias
    UMLS CUI [1,1]
    C0393022
    UMLS CUI [1,2]
    C1301732
    UMLS CUI [2]
    C1514457
    women must be either postmenopausal or sterilized; negative pregnancy test at screening
    Beskrivning

    postmenopausal state, sterilized, pregnancy

    Datatyp

    boolean

    Alias
    UMLS CUI [1]
    C0232970
    UMLS CUI [2]
    C0015787
    UMLS CUI [3]
    C0032961
    participants with total bilirubin below 1.5-fold upper limit of normal (uln) and creatinine below 2-fold uln
    Beskrivning

    total bilirubin, creatinine

    Datatyp

    boolean

    Alias
    UMLS CUI [1]
    C0201913
    UMLS CUI [2]
    C0201976
    participants with karnofsky status greater than or equal to 60 percent
    Beskrivning

    karnofsky

    Datatyp

    boolean

    Alias
    UMLS CUI [1]
    C0206065
    Exclusion Criteria
    Beskrivning

    Exclusion Criteria

    Alias
    UMLS CUI
    C0680251
    participants with previous treatment with bortezomib within 6 months before enrollment or previous treatment with a combination of rituximab and bortezomib
    Beskrivning

    Prior Therapy; bortezomib | Prior Therapy; bortezomib/rituximab

    Datatyp

    boolean

    Alias
    UMLS CUI [1,1]
    C1514463
    UMLS CUI [1,2]
    C1176309
    UMLS CUI [2,1]
    C1514463
    UMLS CUI [2,2]
    C1541445
    participants with previous known allergic reaction to bortezomib, boron or mannitol
    Beskrivning

    previous known allergic reaction to bortezomib, boron or mannitol

    Datatyp

    boolean

    Alias
    UMLS CUI [1,1]
    C0020517
    UMLS CUI [1,2]
    C1176309
    UMLS CUI [2,1]
    C0020517
    UMLS CUI [2,2]
    C0024730
    UMLS CUI [3,1]
    C0020517
    UMLS CUI [3,2]
    C0006030
    participants with life-expectancy of less than 3 months
    Beskrivning

    life-expectancy

    Datatyp

    boolean

    Alias
    UMLS CUI [1]
    C0023671
    participants with malignant neoplasm (cancerous - new growth that is not normal; tumor) (except basalioma) within previous 5 years
    Beskrivning

    history of cancer, basalioma

    Datatyp

    boolean

    Alias
    UMLS CUI [1]
    C2735088
    UMLS CUI [2]
    C0007117
    participants with peripheral (not central) neuropathy (a disturbance in the function of the brain or spinal cord that may affect the nerves and muscles of the body) common terminology criteria for adverse events (ctcae) grade greater than or equal to 2
    Beskrivning

    peripheral neuropathy, common terminology criteria for adverse events (ctcae)

    Datatyp

    boolean

    Alias
    UMLS CUI [1,1]
    C0031117
    UMLS CUI [1,2]
    C3888020
    Tillbaka till toppen

    Similar models

    Eligibility Lymphoma, Follicular NCT01902862

    1 Formulär
    Name
    Typ
    Description | Question | Decode (Coded Value)
    Datatyp
    Alias
    Item Group
    C1512693 (UMLS CUI)
    Lymphoma, Follicular; histological diagnosis; Recurrent disease; Refractory Disease | Lymphoma stage | Cell positive for CD20 antigen
    Item
    participants with histologically confirmed relapsed or refractory follicular stage iii or iv, grade 1 and 2, cluster of differentiation 20 plus (cd20+) lymphoma (who-world health organization) that requires therapy
    boolean
    C0024301 (UMLS CUI [1,1])
    C0679557 (UMLS CUI [1,2])
    C0277556 (UMLS CUI [1,3])
    C1514815 (UMLS CUI [1,4])
    C1272836 (UMLS CUI [2])
    C0882818 (UMLS CUI [3])
    rituximab planned, prior chemotherapy
    Item
    participants in whom treatment with rituximab is planned after greater than or equal to 2 cytostatic (inhibition of cell growth) previous therapies
    boolean
    C0393022 (UMLS CUI [1,1])
    C1301732 (UMLS CUI [1,2])
    C1514457 (UMLS CUI [2])
    postmenopausal state, sterilized, pregnancy
    Item
    women must be either postmenopausal or sterilized; negative pregnancy test at screening
    boolean
    C0232970 (UMLS CUI [1])
    C0015787 (UMLS CUI [2])
    C0032961 (UMLS CUI [3])
    total bilirubin, creatinine
    Item
    participants with total bilirubin below 1.5-fold upper limit of normal (uln) and creatinine below 2-fold uln
    boolean
    C0201913 (UMLS CUI [1])
    C0201976 (UMLS CUI [2])
    karnofsky
    Item
    participants with karnofsky status greater than or equal to 60 percent
    boolean
    C0206065 (UMLS CUI [1])
    Item Group
    C0680251 (UMLS CUI)
    Prior Therapy; bortezomib | Prior Therapy; bortezomib/rituximab
    Item
    participants with previous treatment with bortezomib within 6 months before enrollment or previous treatment with a combination of rituximab and bortezomib
    boolean
    C1514463 (UMLS CUI [1,1])
    C1176309 (UMLS CUI [1,2])
    C1514463 (UMLS CUI [2,1])
    C1541445 (UMLS CUI [2,2])
    previous known allergic reaction to bortezomib, boron or mannitol
    Item
    participants with previous known allergic reaction to bortezomib, boron or mannitol
    boolean
    C0020517 (UMLS CUI [1,1])
    C1176309 (UMLS CUI [1,2])
    C0020517 (UMLS CUI [2,1])
    C0024730 (UMLS CUI [2,2])
    C0020517 (UMLS CUI [3,1])
    C0006030 (UMLS CUI [3,2])
    life-expectancy
    Item
    participants with life-expectancy of less than 3 months
    boolean
    C0023671 (UMLS CUI [1])
    history of cancer, basalioma
    Item
    participants with malignant neoplasm (cancerous - new growth that is not normal; tumor) (except basalioma) within previous 5 years
    boolean
    C2735088 (UMLS CUI [1])
    C0007117 (UMLS CUI [2])
    peripheral neuropathy, common terminology criteria for adverse events (ctcae)
    Item
    participants with peripheral (not central) neuropathy (a disturbance in the function of the brain or spinal cord that may affect the nerves and muscles of the body) common terminology criteria for adverse events (ctcae) grade greater than or equal to 2
    boolean
    C0031117 (UMLS CUI [1,1])
    C3888020 (UMLS CUI [1,2])
    Tillbaka till toppen 

    Hjälp

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial